BiotechTube

tivantinib + omeprazole + s-warfarin + caffeine + digoxin + midazolam

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Solid Tumors

Conditions

Solid Tumors

Trial Timeline

Dec 1, 2011 → Sep 1, 2013

NCT ID
NCT01517399

About tivantinib + omeprazole + s-warfarin + caffeine + digoxin + midazolam

tivantinib + omeprazole + s-warfarin + caffeine + digoxin + midazolam is a phase 1 stage product being developed by Daiichi Sankyo for Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT01517399. Target conditions include Solid Tumors.

What happened to similar drugs?

5 of 13 similar drugs in Solid Tumors were approved

Approved (5) Terminated (2) Active (8)
✅DurvalumabAstraZenecaApproved
✅ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zetaRocheApproved
✅denosumab + pamidronateAmgenApproved
✅Sacituzumab Govitecan-hiyGilead SciencesApproved
✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
🔄MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + TremelimumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01517399Phase 1Completed

Competing Products

20 competing products in Solid Tumors

See all competitors
ProductCompanyStageHype Score
ALG.APV-527Alligator Bioscience ABPhase 1/2
18
ATOR-1017Alligator Bioscience ABPhase 1
19
ATOR-1015Alligator Bioscience ABPhase 1
19
mRNA-4359ModernaPhase 2
0
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
mRNA-2416ModernaPhase 2
0
E7050EisaiPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
18
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
30
BT1718Bicycle TherapeuticsPhase 1/2
22
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
19
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
26